Research Collaboration and Sub-licensing Agreements (Details) € in Thousands					3 Months Ended
	May 07, 2019 protein antibody_and_vaccine	May 05, 2019	Jun. 30, 2017 EUR (€)	Jun. 30, 2017 USD ($)	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)	Apr. 26, 2019	Dec. 31, 2017 EUR (€)	Dec. 31, 2017 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Duration of agreement			2 years	2 years
Payment for research and development agreement			€ 1,000	$ 1,100,000
Prepaid research and development					$ 0		$ 0
Research and development - related party					0	$ 389,473
Collaborative Arrangement | Serum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of antibodies and vaccines for development and commercialization | antibody_and_vaccine	12
Option to obtain exclusive commercial sub-license for number of proteins | protein	12
Research funding, milestone payments and royalties, period	15 years
Revenue from collaborative arrangement, recognized					75,000
Revenue from collaborative arrangement, contract liability					$ 82,000
Novovet
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity percentage								20.00%
Alphazyme
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity percentage		7.50%
Ownership interest consideration receivable upon extension of exclusivity period		2.50%
Alphazyme | Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Exclusivity period		18 months
Option to extend exclusivity period		12 months
RSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment for research and development agreement | €			€ 1,000
Payment for additional development and commercialization | €									€ 1,500
RSA | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			50.00%	50.00%
RSA | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			75.00%	75.00%
RSA | BDI Holdings
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity interest acquired			16.10%	16.10%
RSA | VLPbio
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity interest acquired			3.30%	3.30%
RSA | BDI
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Duration of agreement			2 years	2 years
Obligation for payment for research and development, minimum | €									936
Obligation for payment for research and development, maximum | €									€ 8,000
RSA | BDI | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			50.00%	50.00%
RSA | BDI | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			75.00%	75.00%
SFA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Duration of agreement			2 years	2 years
Obligation for payment for research and development, minimum										$ 1,000,000
Outstanding commitment										$ 1,000,000